Non-Cancer Funding Opportunities

Deadline: Applications accepted on a rolling basis

Amount/Duration: Individual projects requesting up to $10,000 will be considered for small local/community programs. Individual projects requesting up to $20,000 will be considered for a large local/community program.

Eligibility: The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement. If the project involves multiple departments within an institution and/or between different institutions/organizations/associations. all institutions must have a relevant role and the requesting organization must have a key role in the project. For projects offering continuing education credit, the requesting organization must be accredited.

About: Projects that will be considered for Pfizer support will include local/community activities that focus on improving the care of patients by:

• Educating [HCPs] to increase awareness and enable appropriate patient identification by closing knowledge gaps in disease epidemiology, pathophysiology, diagnosis, and emerging treatment paradigms.
• Addressing barriers to appropriate diagnosis and strategies that reduce burdens for patients and providers along the pathway to appropriate diagnosis
• Exploring strategies that empower patients to play an active role in understanding TTR amyloidosis and decision making regarding available diagnostic and treatment options
• Increasing awareness of the changing epidemiology of TTR amyloidosis with a focus on the prevalence of hereditary ATTR and wild-type ATTR subtypes as the science continues to evolve
• Increasing awareness of at risk and undiagnosed populations with TTR amyloidosis with a focus on improving strategies that facilitate the appropriate diagnosis of patients early in the disease course before overt cardiomyopathy has ensued [e.g. populations with electrical disturbances, valvular disease, orthopedic manifestations, and cardio-oncology diseases (i.e. Light Chain Amyloidosis)]
• Addressing geographic and racial healthcare disparities
• Supporting the development of cardiac amyloid centers that provide leadership, best practices, support and/or training of HCPs within a multidisciplinary team environment in order to improve the quality of care for cardiac amyloidosis patients.

More Information

For assistance contact:
Development Office – Corporate and Foundation Relations
honour.harlowe@mountsinai.org
646-605-8715

Application Deadlines: Rolling solicitation
RPF Information Sessions: 8/4/20 & 8/13/20

More Information

Amount/Duration: Up to $100,000 for one year
Eligibility: Not listed About: Funding supports activities that enable states to pre-symptomatically identify and treat pediatric SMA patients through the implementation of newborn screening programs. Possible funded activities include but are not limited to screening implementation support (including pilot screening, assay validation, additional personnel and staff training, equipment needed to perform the assay, and IT resources to perform the assay); and data gathering/patient follow-up and support.

Deadline: Rolling

More Information

Please contact the Development Office’s Corporate and Foundation Relations team for assistance or questions regarding these RFPs: honour.harlowe@mountsinai.org / 646-605-8715

Amount/Duration: up to 500,000 euros for 3 years. Option for extension
About: Projects should focus on pre-outbreak R&D Preparedness for Pandemic disease and response during outreak

Deadline: rolling

More Information

For assistance contact:
Development Office – Corporate and Foundation Relations
honour.harlowe@mountsinai.org
646-605-8715

Several PCORI Funding Announcements (PFAs) for 2021 will open on January 5, 2021. Our Broad PFA seeks proposals for comparative clinical effectiveness research projects aligned with our priority areas for research. We will also accept proposals for studies on improving methods to conduct patient-centered outcomes research and implementing PCORI-funded research results. Additionally, our first Pragmatic Clinical Studies PFA since 2018 will open. Letters of Intent for these opportunities are due in late January or early February, depending on the PFA.

More Information

SEED is a funding program that will provide supplements to existing grants for the recruitment of new lab members from American underrepresented minority groups at the postdoctoral level.

Deadline: rolling

More Information

Amount/Duration: Individual basic science project requesting up to $90,000/year for 1 to 2-year projects will be considered. Individual clinical science projects requesting up to $70,000/year for 1 to 2-year projects will be considered. Young Investigator basic or clinical projects requesting up to $70,000/year for 1 to 2-year projects will be considered.
Eligibility: Only organizations are eligible to receive grants, not individuals or medical practice groups, The applicant (PI) must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work, For the
Young Investigator award, the PI must have received this degree within the last 7 years, Applicant must be affiliated with a host institution.
About: Projects that will be considered for Pfizer support will focus on the following areas: Basic and Clinical Science of Gene Therapy for Hemophilia, Basic and Clinical Science of Tissue Factor Pathway Inhibitor (TFPI) and anti-TFPI monoclonal antibodies, Burden of disease: Clinical Hemophilia A and B.

Application Deadline: Mar 1, 2021

More Information

Deadline: March 15, 2021

Amount/Duration: Up to $100,000

Eligibility: See website.

About: The mission of the Angelman Syndrome Foundation is to advance the awareness and treatment of Angelman syndrome through education and information, research, and support for individuals with Angelman syndrome, their families, and other concerned parties. Grants will be awarded in support of research focused on gastrointestinal complications in Angelman syndrome.

More Information

For assistance contact:
Development Office – Corporate and Foundation Relations
honour.harlowe@mountsinai.org
646-605-8715

Public Health Solutions (PHS), on behalf of the New York City (NYC) Department of Health and Mental Hygiene (DOHMH), Bureau of HIV (BHIV), has released the Request for Proposals (RFP) for Psychosocial Support Services for Transgender, Intersex, Gender Non-Con

Proposal Deadline: March 18, 2021

More Information

Deadline: March 21, 2021

Amount/Duration: Up to $40,000 over up to two years

Eligibility: To be eligible, at least one member of the research team must hold a PhD, MD, or equivalent; and maintain a faculty position or equivalent at a college, university, medical school, or another research facility. International researchers are eligible to apply.

About: OAR seeks to fund studies that expand the body of knowledge related to autism intervention and treatment, produce practical and clearly objective results, and have the potential to impact public policy.
OAR is placing an emphasis on research that addresses the following areas:
• Community-Based Assessment and Intervention for Challenging Behavior
• Community-Engaged Research
• Effectiveness of Augmentative Communication Systems
• Healthcare Transition / Across the Lifespan
• Improving Access to and Effectiveness of Existing Systems and Services
• Integrated Employment
• Intersectionality, Equity and Diversity
• Mental Health Assessment and Intervention
• Mid-life and Older Adults
• Residential/Community Services and Supports

More Information

For assistance contact:
Development Office – Corporate and Foundation Relations
honour.harlowe@mountsinai.org
646-605-8715

Deadline: March 24, 2021

Amount/Duration: Up to $500,000 for up to three years

Eligibility: Scientists of any nationality holding a PhD, ScD, MD, DVM, or DrPH degree are eligible to apply. About: Research projects are often interdisciplinary in nature and span a range of scientific fields, including atmospheric science, epidemiology, exposure science, statistics, and toxicology. In considering potential research topics, applicants should be aware of HEI’s current priorities, which this year are focused on four key areas: multipollutant science; accountability and transparency; emerging technologies and fuels; and global health science.

More Information

For assistance contact:
Development Office – Corporate and Foundation Relations
honour.harlowe@mountsinai.org
646-605-8715

Deadline: March 24, 2021

Amount/Duration: Up to $50,000 for one year

Eligibility: To be eligible, the principal investigator(s) should be members of the American Epilepsy Society and the principal investigator should be at an academic research institution in the United States. Collaborators with international academic research institutions as well as nonprofit or for-profit organizations are eligible.

About: The program aims to facilitate the creation of national or international multi-center research programs, and proposals are welcomed across the spectrum of research on epilepsy, seizures, and related disorders, including basic, translational, and clinical. Grants will be awarded in support of organizational planning sessions, infrastructure development, and/or pilot projects that enable the research program to compete for subsequent investment by other organizations.

More Information

For assistance contact:
Development Office – Corporate and Foundation Relations
honour.harlowe@mountsinai.org
646-605-8715

Deadline: March 25, 2021

Amount/Duration: $375,000 over five years

Eligibility: To be eligible, applicants must possess an MD, DO, or recognized equivalent foreign degree and be in their first, second, or third year of a junior faculty appointment. Applicants need not be a citizen of the United States.

About: Grants will be awarded to junior investigators eager to pursue vigorous research on therapies and cures for retinal degenerative diseases (i.e., inherited orphan retinal degenerative diseases and non-exudative age-related macular degeneration). The goal of the program is to facilitate advances in laboratory and clinical research, elucidate the mechanisms for the etiology and pathogenesis of RDDs, and develop innovative strategies for the prevention, treatment, and cure for these diseases.

More Information

For assistance contact:
Development Office – Corporate and Foundation Relations
honour.harlowe@mountsinai.org
646-605-8715

Deadline: April 1, 2021

Amount/Duration: $50,000

Eligibility: The Fauci Fellowships will be awarded to one Italian researcher and one Italian American researcher who have completed all the requirements for a Ph.D. in one of the following subjects: medicine, biological sciences, pharmacy, chemistry, or other scientific disciplines, as well as a strong record of research accomplishments and publications in the biomedical field. Previous experience in the virus and cancer fields will be highly regarded. Preference will be given to applicants who have earned their Ph.D. in an eligible field in the past eight years.

About: In recognition of Dr. Anthony S. Fauci’s life-saving work, the National Italian American Foundation (NIAF) has established the Fauci Fellowships. Through this program, the Foundation is offering two $50,000 post-doctoral research grants that will be awarded to an Italian researcher working in Italy and an Italian American researcher working in the United States to support research in infectious diseases and help establish both recipients’ independent careers.

More Information

For assistance contact:
Development Office – Corporate and Foundation Relations
honour.harlowe@mountsinai.org
646-605-8715

Deadline: April 8, 2021

Amount/Duration: Up to $50,000

Eligibility: The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement. If the project involves multiple departments within an institution and/or between different institutions/organizations/associations. All institutions must have a relevant role and the requesting organization must have a key role in the project. For projects offering continuing education credit, the requesting organization must be accredited.

About: Projects that will be considered for Pfizer support will focus on supporting the development of cardiac amyloid centers that provide leadership, best practices, support and/or training of HCPs within a multidisciplinary team environment in order to improve the quality of care for cardiac amyloidosis patients.

More Information

For assistance contact:
Development Office – Corporate and Foundation Relations
honour.harlowe@mountsinai.org
646-605-8715

The National Center for Advancing Translational Sciences (NCATS) has reissued its cooperative agreement opportunity using the “basket clinical trial” approach to support clinical trials of drugs that target molecular defects common to more than one rare disease.

Projects proposed for this FOA will require individuals with expertise in carrying out clinical trials in rare diseases. Applicants are strongly encouraged to collaborate with investigators at academic institutions and negotiate an agreement for carrying out the proposed clinical trials. NCATS will give priority to projects involving clinical investigators who are part of the Rare Disease Clinical Research Network (RDCRN) and who focus on diseases under study in the RDCRN.

More Information

Deadline: April 13, 2021 by 5:00 p.m. ET.

Deadline: April 15, 2021

Amount/Duration: Up to $150,000

Eligibility: The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement

About: Projects that will be considered for Pfizer support will focus on improving the care of patients by:
• Educating [HCPs] to increase awareness and enable appropriate patient identification by closing knowledge gaps in disease epidemiology, pathophysiology, diagnosis, and emerging treatment paradigms.
• Addressing barriers to appropriate diagnosis and strategies that reduce burdens for patients and providers along the pathway to appropriate diagnosis.
• Exploring strategies that empower patients to play an active role in understanding TTR amyloidosis and decision making regarding available diagnostic and treatment options
• Increasing awareness of the changing epidemiology of TTR amyloidosis with a focus on the prevalence of hereditary ATTR and wild-type ATTR subtypes as the science continues to evolve
• Increasing awareness of at-risk and undiagnosed populations with TTR amyloidosis with a focus on improving strategies that facilitate the appropriate diagnosis of patients early in the disease course before overt cardiomyopathy has ensued [e.g. populations with electrical disturbances, valvular disease, orthopedic manifestations, and cardio-oncology diseases (i.e. Light Chain Amyloidosis).

More Information

For assistance contact:
Development Office – Corporate and Foundation Relations
honour.harlowe@mountsinai.org
646-605-8715

Deadline: June 15, 2021

Amount/Duration: $80,000 for one year

Eligibility: Accredited, US-based academic institution. This grant will be awarded to an institution, not an individual. Institutions with fellowship programs that include independent research and a strong mentoring program. Clinical training may be included in the program but is not required. No aspect of the fellowship program can benefit Pfizer’s business or a Pfizer asset.

About: It is our intent to support institutions with fellowship programs for Cardiologists that have a strong focus on clinical practice, research, and education to further the understanding of transthyretin cardiac amyloidosis.

More Information

For assistance contact:
Development Office – Corporate and Foundation Relations
honour.harlowe@mountsinai.org
646-605-8715